FDA Opens Comment Period for Planned Changes to 510(k) Process

Clinical labs have until Aug. 15 to comment on the plan, which aims to improve the 510(k)-review and -approval process, and, possibly, contribute to a fair and sensible dénouement to the agency's new LDT-regulatory scheme.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.